The ratio of ursodeoxycholyltaurine to 7‐oxolithocholyltaurine serves as a biomarker of decreased 11β‐hydroxysteroid dehydrogenase 1 activity in mouse
Open Access
- 15 January 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (16), 3309-3326
- https://doi.org/10.1111/bph.15367
Abstract
Background and Purpose 11β‐hydroxysteroid dehydrogenase 1 (11β‐HSD1) regulates tissue‐specific glucocorticoid metabolism, and its impaired expression and activity is associated with major diseases. Pharmacological inhibition of 11β‐HSD1 is considered a promising therapeutic strategy. This study investigated whether alternative 7‐oxo bile acid substrates of 11β‐HSD1 or the ratios to their 7‐hydroxy products can serve as biomarkers for decreased enzymatic activity. Experimental Approach Bile acid profiles were measured by ultra‐high performance liquid chromatography tandem‐mass spectrometry in plasma and liver tissue samples of four different mouse models with decreased 11β‐HSD1 activity: global (11KO) and liver‐specific 11β‐HSD1 knockout mice (11LKO), mice lacking hexose‐6‐phosphate dehydrogenase (H6pdKO) that provides cofactor NADPH for 11β‐HSD1, and mice treated with the pharmacological inhibitor carbenoxolone (CBX). Additionally, 11β‐HSD1 expression and activity were assessed in H6pdKO and CBX treated mice. Key Results The enzyme product to substrate ratios were more reliable markers of 11β‐HSD1 activity than absolute levels due to large inter‐individual variations in bile acid concentrations. The ratio of the 7β‐hydroxylated ursodeoxycholyltaurine (UDC‐Tau) to 7‐oxolithocholyltaurine (7oxoLC‐Tau) was diminished in plasma and liver tissue of all four mouse models, and decreased in H6pdKO and CBX treated mice with moderately reduced 11β‐HSD1 activity. The persistence of 11β‐HSD1 oxoreduction activity in the face of H6PD loss indicates the existence of an alternative NADPH source in the endoplasmic reticulum. Conclusions and Implications The plasma UDC‐Tau/7oxo‐LC‐Tau ratio detects decreased 11β‐HSD1 oxoreduction activity in different mouse models. This ratio may be a useful biomarker of decreased 11β‐HSD1 activity in patho‐physiological situations or upon pharmacological inhibition.Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A‐179400 (to A.O.))
This publication has 57 references indexed in Scilit:
- Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acidJournal of Lipid Research, 2013
- Novel H6PDH mutations in two girls with premature adrenarche: ‘apparent’ and ‘true’ CRD can be differentiated by urinary steroid profilingActa Endocrinologica, 2013
- Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11β-Hydroxysteroid Dehydrogenase Type 1Endocrinology, 2012
- Biomarkers of hypothalamic–pituitary–adrenal axis activity in mice lacking 11β-HSD1 and H6PDHJournal of Endocrinology, 2012
- Isolated cortisol deficiency: A rare cause of neonatal cholestasisSaudi Journal of Gastroenterology, 2012
- 11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progressFrontiers in Neuroendocrinology, 2011
- Hexose-6-Phosphate Dehydrogenase Contributes to Skeletal Muscle Homeostasis Independent of 11β-Hydroxysteroid Dehydrogenase Type 1Endocrinology, 2011
- The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyDiabetes Care, 2010
- Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC–MS/MSJournal of Chromatography B, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008